サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1631234

CGRP阻害剤の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）

CGRP Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032

出版日
ページ情報
英文 213 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
CGRP阻害剤の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2032年）
出版日: 2025年01月06日
発行: Fairfield Market Research
ページ情報: 英文 213 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のCGRP阻害剤の市場規模は、世界の片頭痛の有病率の上昇により需要が急増しています。これらの阻害剤は画期的な医薬品であり、片頭痛開発の鍵を握るカルシトニン遺伝子関連ペプチド（CGRP）を標的とします。CGRPの活性を阻害することにより、片頭痛の頻度と重症度を著しく減少させます。年間平均成長率（CAGR）は13.90%と予測されており、この市場は大幅な成長を遂げ、片頭痛管理を再構築し、世界中の数100万人の生活の質を向上させる、的を絞った効果的なソリューションを提供します。

CGRP阻害剤は、片頭痛の発症に重要な役割を果たす神経ペプチドであるカルシトニン遺伝子関連ペプチド（CGRP）の活性を調節することによって作用します。CGRPが受容体に結合するのを阻止するか、その放出を阻害することによって、これらの阻害剤は片頭痛の頻度と重症度を有意に減少させます。慢性片頭痛の予防治療薬として、CGRP阻害剤はこの衰弱症状の治療分析を再構築しています。

CGRP阻害剤の世界市場は、片頭痛治療薬の進歩や、患者やヘルスケアプロバイダーの意識の高まりに牽引され、大きな成長を遂げるとみられています。革新的なソリューションと戦略的提携により、市場参入企業は効果的な片頭痛治療に対する需要の高まりに対応する態勢を整えています。分析が進化するにつれ、CGRP阻害剤は片頭痛管理の標準を再定義し続け、世界中の何100万人もの人々に希望と生活の質の向上をもたらします。

片頭痛の世界の増加により、標的を絞った治療介入が必要となり、CGRP阻害剤の需要を牽引しています。CGRP阻害剤の標的メカニズムは、従来の治療と比較して高い有効性と優れた安全性プロファイルを提供し、その採用を増加させます。CGRP阻害剤の登場は、精密医療と個別化医療を重視する片頭痛治療におけるパラダイムシフトを強調するものです。ヘルスケアプロバイダーは、片頭痛の予防的治療が患者にとって長期的に有益であることを認識し、鎮痛薬への依存を減らすため、ますます支持するようになっています。啓蒙キャンペーンや教育イニシアティブは、患者に高度な片頭痛治療の選択肢を知らせる上で極めて重要な役割を果たしており、CGRP阻害剤の需要をさらに押し上げています。

当レポートでは、世界のCGRP阻害剤市場について調査し、市場の概要とともに、分子別、治療別、投与経路別、最終用途別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナ・ロシア紛争の影響
  • 経済概要
  • PESTLE分析

第3章 生産高と貿易統計、2019年～2023年

第4章 価格分析、2019年～2023年

第5章 世界のCGRP阻害剤市場の見通し、2019年～2032年

  • 世界のCGRP阻害剤市場の見通し、分子別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界のCGRP阻害剤市場の見通し、治療別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界のCGRP阻害剤市場の見通し、投与経路別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界のCGRP阻害剤市場の見通し、最終用途別、金額（10億米ドル）、数量（100万個）、2019年～2032年
  • 世界のCGRP阻害剤市場の見通し、地域別、金額（10億米ドル）、数量（100万個）、2019年～2032年

第6章 北米のCGRP阻害剤市場の見通し、2019年～2032年

第7章 欧州のCGRP阻害剤市場の見通し、2019年～2032年

第8章 アジア太平洋のCGRP阻害剤市場の見通し、2019年～2032年

第9章 ラテンアメリカのCGRP阻害剤市場の見通し、2019年～2032年

第10章 中東・アフリカのCGRP阻害剤市場の見通し、2019年～2032年

第11章 競合情勢

  • 投与経路別と治療別ヒートマップ
  • メーカー別と治療別ヒートマップ
  • 企業市場シェア分析、2022年
  • 競合ダッシュボード
  • 企業プロファイル
    • Amgen
    • Novartis
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly
    • Lundbeck
    • Abbvie
    • Allergan

第12章 付録

目次

The global CGRP inhibitors market is experiencing a surge in demand due to the rising prevalence of migraines worldwide. These inhibitors, a groundbreaking class of pharmaceuticals, target the calcitonin gene-related peptide (CGRP), a key player in migraine development. By preventing CGRP activity, they significantly reduce the frequency and severity of migraines. With a projected compound annual growth rate (CAGR) of 13.90%, the market is poised to achieve substantial growth, offering targeted and effective solutions that are reshaping migraine management and improving the quality of life for millions globally.

Market Insights

CGRP inhibitors work by modulating the activity of the calcitonin gene-related peptide (CGRP), a neuropeptide that plays a significant role in migraine pathogenesis. By preventing CGRP from binding to its receptors or blocking its release, these inhibitors significantly reduce migraine frequency and severity. As preventive treatments for chronic migraines, CGRP inhibitors are reshaping the therapeutic Analysis for this debilitating condition.

The global CGRP inhibitors market is set to witness significant growth, driven by advancements in migraine therapeutics and increasing awareness among patients and healthcare providers. With innovative solutions and strategic collaborations, the market players are well-positioned to address the growing demand for effective migraine treatments. As the Analysis evolves, CGRP inhibitors continue to redefine the standards of care in migraine management, offering hope and improved quality of life for millions worldwide.

Key Market Drivers

  • Rising Migraine Prevalence: The growing global burden of migraines necessitates targeted therapeutic interventions, driving the demand for CGRP inhibitors.
  • Effectiveness and Precision: The targeted mechanism of CGRP inhibitors offers higher efficacy and better safety profiles compared to traditional treatments, increasing their adoption.
  • Advancements in Migraine Care: The emergence of CGRP inhibitors underscores a paradigm shift in migraine therapeutics, emphasizing precision medicine and personalized care.
  • Shifting Treatment Paradigms: Healthcare providers are increasingly favoring preventive migraine treatments, recognizing their long-term benefits for patients and reducing reliance on pain-relief medications.
  • Growing Awareness Among Patients: Awareness campaigns and educational initiatives have played a pivotal role in informing patients about advanced migraine treatment options, further driving demand for CGRP inhibitors.

Business Opportunities

  • Combination Therapies: Exploring combination treatments involving CGRP inhibitors and other migraine management modalities presents a promising avenue for innovation and revenue growth.
  • Strategic Partnerships: Collaborations between pharmaceutical companies, healthcare institutions, and research organizations can enhance awareness, accessibility, and affordability of CGRP inhibitors.
  • Patient-Centric Solutions: Developing non-invasive and patient-friendly delivery methods, such as nasal sprays, can further expand the market reach.

Regional Analysis

  • Europe: As the leading region, Europe is driving market growth through strategic healthcare initiatives, a robust regulatory framework, and a strong focus on advanced migraine therapies.
  • South Asia & Pacific: This region is the fastest-growing market, supported by a rising migraine burden, increased awareness of innovative treatments, and improved healthcare access.
  • North America: The region's advanced healthcare infrastructure and high adoption rates for innovative therapies position it as a critical market for CGRP inhibitors.

Key Players

Prominent companies in the CGRP inhibitors market include:

  • Amgen
  • Novartis
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly
  • Lundbeck
  • Abbvie
  • Allergan

These organizations are at the forefront of research and development, introducing innovative therapies and expanding their product portfolios to maintain a competitive edge.

Market Segmentation

1. By Molecule:

    Small Molecule Large Molecule

2. By Treatment:

    Preventive Migraine Treatment Acute Migraine Treatment

3. By Route of Administration:

    Oral Nasal Injectables

4. By End-Use:

    Hospitals Specialty Clinics Mail Order Pharmacies Retail Pharmacies

5. By Region:

    North America Europe Asia Pacific Latin America Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global CGRP Inhibitors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Volume and Value, 2024
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact Of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. Pestle Analysis

3. Production Output and Trade Statistics, 2019 - 2023

  • 3.1. Global CGRP Inhibitors Market Production Output, by Region, Value (US$ Bn) and Volume (Million Units),2019 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2019 - 2023

  • 4.1. Global Average Price Analysis, by Type, US$ Per Unit, 2019 - 2023
  • 4.2. Prominent Factor Affecting CGRP Inhibitors Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit, 2019 - 2023

5. Global CGRP Inhibitors Market Outlook, 2019 - 2032

  • 5.1. Global CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.1.1. Key Highlights
      • 5.1.1.1. Small Molecule
      • 5.1.1.2. Large Molecule
  • 5.2. Global CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.2.1. Key Highlights
      • 5.2.1.1. Preventive Migraine Treatment
      • 5.2.1.2. Acute Migraine Treatment
  • 5.3. Global CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Nasal
      • 5.3.1.3. Injectables
  • 5.4. Global CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospitals
      • 5.4.1.2. Specialty Clinics
      • 5.4.1.3. Mail Order Pharmacies
      • 5.4.1.4. Retail Pharmacies
  • 5.5. Global CGRP Inhibitors Market Outlook, by Region, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 6.1. North America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.1.1. Key Highlights
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Large Molecule
  • 6.2. North America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.2.1. Key Highlights
      • 6.2.1.1. Preventive Migraine Treatment
      • 6.2.1.2. Acute Migraine Treatment
  • 6.3. North America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Nasal
      • 6.3.1.3. Injectables
  • 6.4. North America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospitals
      • 6.4.1.2. Specialty Clinics
      • 6.4.1.3. Mail Order Pharmacies
      • 6.4.1.4. Retail Pharmacies
  • 6.5. North America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.2. U.S. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.3. U.S. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.4. U.S. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.5. Canada CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.6. Canada CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.7. Canada CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 6.5.1.8. Canada CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe CGRP Inhibitors Market Outlook, 2019 - 2032

  • 7.1. Europe CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.1.1. Key Highlights
      • 7.1.1.1. Small Molecule
      • 7.1.1.2. Large Molecule
  • 7.2. Europe CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.2.1. Key Highlights
      • 7.2.1.1. Preventive Migraine Treatment
      • 7.2.1.2. Acute Migraine Treatment
  • 7.3. Europe CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Nasal
      • 7.3.1.3. Injectables
  • 7.4. Europe CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospitals
      • 7.4.1.2. Specialty Clinics
      • 7.4.1.3. Mail Order Pharmacies
      • 7.4.1.4. Retail Pharmacies
  • 7.5. Europe CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.2. Germany CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.3. Germany CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.4. Germany CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.5. U.K. CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.6. U.K. CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.7. U.K. CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.8. U.K. CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.9. France CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.10. France CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.11. France CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.12. France CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.13. Italy CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.14. Italy CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.15. Italy CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.16. Italy CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.17. Turkey CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.18. Turkey CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.19. Turkey CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.20. Turkey CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.21. Russia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.22. Russia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.23. Russia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.24. Russia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.25. Rest Of Europe CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.26. Rest Of Europe CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.27. Rest Of Europe CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 7.5.1.28. Rest of Europe CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific CGRP Inhibitors Market Outlook, 2019 - 2032

  • 8.1. Asia Pacific CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.1.1. Key Highlights
      • 8.1.1.1. Small Molecule
      • 8.1.1.2. Large Molecule
  • 8.2. Asia Pacific CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.2.1. Key Highlights
      • 8.2.1.1. Preventive Migraine Treatment
      • 8.2.1.2. Acute Migraine Treatment
  • 8.3. Asia Pacific CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Nasal
      • 8.3.1.3. Injectables
  • 8.4. Asia Pacific CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospitals
      • 8.4.1.2. Specialty Clinics
      • 8.4.1.3. Mail Order Pharmacies
      • 8.4.1.4. Retail Pharmacies
  • 8.5. Asia Pacific CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.1. Key Highlights
      • 8.5.1.1. China CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.2. China CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.3. China CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.4. China CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.5. Japan CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.6. Japan CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.7. Japan CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.8. Japan CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.9. South Korea CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.10. South Korea CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.11. South Korea CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.12. South Korea CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.13. India CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.14. India CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.15. India CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.16. India CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.17. Southeast Asia CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.18. Southeast Asia CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.19. Southeast Asia CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.20. Southeast Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.21. Rest Of Asia Pacific CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.22. Rest Of Asia Pacific CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.23. Rest Of Asia Pacific CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 8.5.1.24. Rest of Asia CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America CGRP Inhibitors Market Outlook, 2019 - 2032

  • 9.1. Latin America CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.1.1. Key Highlights
      • 9.1.1.1. Small Molecule
      • 9.1.1.2. Large Molecule
  • 9.2. Latin America CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.2.1. Key Highlights
      • 9.2.1.1. Preventive Migraine Treatment
      • 9.2.1.2. Acute Migraine Treatment
  • 9.3. Latin America CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Nasal
      • 9.3.1.3. Injectables
  • 9.4. Latin America CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospitals
      • 9.4.1.2. Specialty Clinics
      • 9.4.1.3. Mail Order Pharmacies
      • 9.4.1.4. Retail Pharmacies
  • 9.5. Latin America CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.2. Brazil CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.3. Brazil CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.4. Brazil CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.5. Mexico CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.6. Mexico CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.7. Mexico CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.8. Mexico CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.9. Argentina CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.10. Argentina CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.11. Argentina CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.12. Argentina CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.13. Rest Of Latin America CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.14. Rest Of Latin America CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.15. Rest Of Latin America CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 9.5.1.16. Rest of Latin America CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa CGRP Inhibitors Market Outlook, 2019 - 2032

  • 10.1. Middle East & Africa CGRP Inhibitors Market Outlook, by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.1.1. Key Highlights
      • 10.1.1.1. Small Molecule
      • 10.1.1.2. Large Molecule
  • 10.2. Middle East & Africa CGRP Inhibitors Market Outlook, by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.2.1. Key Highlights
      • 10.2.1.1. Preventive Migraine Treatment
      • 10.2.1.2. Acute Migraine Treatment
  • 10.3. Middle East & Africa CGRP Inhibitors Market Outlook, by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Nasal
      • 10.3.1.3. Injectables
  • 10.4. Middle East & Africa CGRP Inhibitors Market Outlook, by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospitals
      • 10.4.1.2. Specialty Clinics
      • 10.4.1.3. Mail Order Pharmacies
      • 10.4.1.4. Retail Pharmacies
  • 10.5. Middle East & Africa CGRP Inhibitors Market Outlook, by Country, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.2. GCC CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.3. GCC CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.4. GCC CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.5. South Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.6. South Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.7. South Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.8. South Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.9. Egypt CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.10. Egypt CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.11. Egypt CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.12. Egypt CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.13. Nigeria CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.14. Nigeria CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.15. Nigeria CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.16. Nigeria CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.17. Rest Of Middle East & Africa CGRP Inhibitors Market by Molecule, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.18. Rest Of Middle East & Africa CGRP Inhibitors Market by Treatment, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.19. Rest Of Middle East & Africa CGRP Inhibitors Market by Route of Administration, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
      • 10.5.1.20. Rest of Middle East & Africa CGRP Inhibitors Market by End-Use, Value (US$ Bn) and Volume (Million Units), 2019 - 2032
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. By Route of Administration Vs by Treatment Heat Map
  • 11.2. Manufacturer Vs by Treatment Heatmap
  • 11.3. Company Market Share Analysis, 2022
  • 11.4. Competitive Dashboard
  • 11.5. Company Profiles
    • 11.5.1. Amgen
      • 11.5.1.1. Company Overview
      • 11.5.1.2. Type Portfolio
      • 11.5.1.3. Financial Overview
      • 11.5.1.4. Business Strategies and Development
    • 11.5.2. Novartis
      • 11.5.2.1. Company Overview
      • 11.5.2.2. Type Portfolio
      • 11.5.2.3. Financial Overview
      • 11.5.2.4. Business Strategies and Development
    • 11.5.3. Teva Pharmaceutical Industries Ltd.
      • 11.5.3.1. Company Overview
      • 11.5.3.2. Type Portfolio
      • 11.5.3.3. Financial Overview
      • 11.5.3.4. Business Strategies and Development
    • 11.5.4. Eli Lilly
      • 11.5.4.1. Company Overview
      • 11.5.4.2. Type Portfolio
      • 11.5.4.3. Financial Overview
      • 11.5.4.4. Business Strategies and Development
    • 11.5.5. Lundbeck
      • 11.5.5.1. Company Overview
      • 11.5.5.2. Type Portfolio
      • 11.5.5.3. Financial Overview
      • 11.5.5.4. Business Strategies and Development
    • 11.5.6. Abbvie
      • 11.5.6.1. Company Overview
      • 11.5.6.2. Type Portfolio
      • 11.5.6.3. Financial Overview
      • 11.5.6.4. Business Strategies and Development
    • 11.5.7. Allergan
      • 11.5.7.1. Company Overview
      • 11.5.7.2. Type Portfolio
      • 11.5.7.3. Financial Overview
      • 11.5.7.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms And Abbreviations